🇺🇸 FDA
Patent

US 9399627

Substituted macrocyclic compounds having proteasome inhibitory activity

granted A61KA61K31/395A61K45/06

Quick answer

US patent 9399627 (Substituted macrocyclic compounds having proteasome inhibitory activity) held by The Regents of the University of California expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jul 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/395, A61K45/06, A61P, A61P35/00